Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Resource Type
Academic Journal
Authors
González-Martín A; Medical Oncology Department, Cancer Center Clínica Universidad de Navarra, Madrid, Program in Solid Tumours, CIMA, Pamplona, & Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain.; Pothuri B; Gynecologic Oncology Group (GOG Foundation), NYU Langone Health, Department of Obstetrics & Gynecology, Perlmutter Cancer Center, New York, NY, USA.; Vergote I; Belgium & Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology & Obstetrics, Division of Gynaecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium, European Union.; Graybill W; GOG, Gynecologic Oncology, Medical University of South Carolina, Charleston, SC, USA.; Lorusso D; Multicentre Italian Trials in Ovarian Cancer & Gynecologic Malignancies (MITO), Fondazione Policlinico Gemelli IRCCS & Catholic University of Sacred Heart, Rome, Italy, when the study was conducted; present affiliation Humanitas San Pio X, Milan, Humanitas University, Rozzano, Italy.; McCormick CC; GOG, Legacy Medical Group Gynecologic Oncology, Portland, OR, USA.; Freyer G; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), HCL Cancer Institute, Department of Medical Oncology, Lyon University, Lyon, France.; Backes F; Division of Gynecologic Oncology, Ohio State University, Columbus, OH, USA.; Heitz F; AGO Study Group & the Department for Gynaecology & Gynaecologic Oncology, Kliniken Essen-Mitte, Essen, & Charité - Universitätsmedizin Berlin, Humboldt- Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, Germany.; Redondo A; GEICO, Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; Moore RG; Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics & Gynecology, University of Rochester, Rochester, NY, USA.; Vulsteke C; BGOG, Department of Medical Oncology & Hematology, AZ Maria Middelares, Gent, & Department of Molecular Imaging, Pathology, Radiotherapy & Oncology, Center for Oncological Research, Antwerp University, Antwerp, Belgium.; O'Cearbhaill RE; GOG, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, & Department of Medicine, Weill Cornell Medical College, New York, NY, USA.; Malinowska IA; GSK, Middlesex, UK.; Shtessel L; GSK, Middlesex, UK.; Compton N; GSK, Middlesex, UK.; Mirza MR; Department of Oncology, Rigshospitalet-Copenhagen University Hospital & Nordic Society of Gynaecological Oncology, Copenhagen, Denmark.; Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix Creighton University, Phoenix, AZ, USA, when the study was conducted; present affiliation GOG Foundation; Florida Cancer Specialists & Research Institute, West Palm Beach, FL, USA.
Source
Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE